Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amivutamab Monotherapy in RAS Wild-type Metastatic Colorectal Cancer
CTR20192641Phase 2Active
- Sponsor
- Shanghai Sailon Biotechnology
- Start
- Jan 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of amivutamab in colorectal cancer (CRC), sponsored by Shanghai Sailon Biotechnology. Started Jan 2020; status: active.
02
Drugs
amivutamab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on CTR20192641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20192641.